Regional myocardial blood flow in stable angina pectoris associated with isolated significant narrowing of either the left anterior descending or left circumflex coronary artery

https://doi.org/10.1016/0002-9149(93)90850-CGet rights and content

Abstract

Myocardial perfusion measurements were obtained with positron emission tomography under basal conditions and after intravenous dipyridamole infusion (0.56 mg/kg over 4 minutes) to determine if myocardial perfusion is maximized in areas of resting wall motion abnormalities in patients with stable angina. Thirty-three patients with no history of myocardial infarction, and with coronary stenosis >50% involving the left anterior descending (n = 24) and left circumflex (n = 9) coronary arteries were evaluated. Quantitative perfusion images were recorded twice in each subject using nitrogen-13 ammonia at baseline and after intravenous administration of dipyridamole. Computer-assisted analysis of left ventriculograms showed abnormal wall motion in the stenosis-related regions in 16 patients (group 1), and normal regional function in 17 (group 2). The flow values in the anterior and posterolateral wall were considered to reflect left anterior and left circumflex coronary artery flow, respectively. Quantitative angiography showed that coronary stenosis severity was higher in group 1 than in group 2 (cross-sectional area reduction 94 ± 7% vs 87 ± 11%; p <0.05). Resting blood flow in the stenosis-related areas was significantly lower than in contralateral regions in group 1(0.66 ± 0.19 vs 0.77 ± 0.26 ml/min/r, p <0.05), but not in group 2 (0.73 ± 0.18 vs 0.78 ± 0.21 ml/min/g; p = NS). Dipyridamole significantly (p <0.01) increased myocardial blood flow in both stenotic and remote regions in both groups 1(0.95 ± 0.41 vs 1.57 ± 0.70 ml/min/10 and 2 (1.54 ± 0.53 vs 2.01 ± 0.84 ml/ min/g). Thus, in patients with stable angina and no previous myocardial infarction, chronic wall motion abnormalities may be associated with reduced myocardial blood flow. A residual vascular tone can be maintained in hypoperfused dysfunctioning myocardial areas, suggesting that further factors, in addition to the restriction in oxygen delivery, can downregulate the metabolic demand of hibemating myocardium.

References (30)

  • F.J. Klocke et al.

    Average coronary blood flow per unit weight of left ventricle in patients with and without coronary artery disease

    Circulation

    (1974)
  • L.K. Gould et al.

    Compensatory changes of the distal coronary vascular bed during progressive coronary constriction

    Circulation

    (1975)
  • J.M. Canty et al.

    Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve

    Circulation

    (1985)
  • T. Aversano et al.

    Persistence of coronary vasodilator reserve despite functionally significant flow reduction

    Am J Physiol

    (1985)
  • G.A. Pantely et al.

    Incomplete coronary vasodilation during myocardial ischemia in swine

    Am J Physiol

    (1985)
  • Cited by (37)

    • Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Results From the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) Study

      2010, Journal of the American College of Cardiology
      Citation Excerpt :

      Finally, reduced MBF reserve in patients with hypertrophic (9) or dilated cardiomyopathy (29) has predictive value for prognosis. Thus, the overall topic of coronary microvascular dysfunction and its clinical implications has increasing interest (11–13,15–18,38–43). A better understanding of adverse outcomes associated with dysfunctional microvessels could help to clarify the pathophysiology of ischemic heart disease in women and perhaps identify new targets for both diagnostic testing and therapeutic intervention.

    • Coronary microvascular dysfunction

      2007, New England Journal of Medicine
    View all citing articles on Scopus

    This study was supported in part by the CNR-Targeted Project “Prevention and Control of Disease Factors,” Subproject “Control of Cardiovascular Disease,” from the National Research Council, Rome, Italy, and by a grant from Knoll Pharmaceutics, Milan, Italy.

    View full text